The designation stems from the positive results of the Embrave Part A clinical trial, which demonstrated substantial clinical benefits sustained for up to a year. By streamlining the development and review process, the FDA aims to accelerate the availability of this therapy for a condition that previously lacked robust treatment options. The company is currently enrolling patients in the pivotal Embrave3 study, utilizing a single-arm design that has already received agency alignment.

Beyond this latest milestone, elsunersen carries rare pediatric disease and orphan drug designations in the United States, alongside additional orphan status in Europe. Investors have responded favorably to the news, pushing the stock up 13% over the trailing five-day period as the company advances toward its next regulatory milestones.